Cargando…

Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is now a serious public health problem. Angiotensin-converting enzyme 2 (ACE2) recognized as the receptor of SARS-CoV is also necessary for SARS-CoV-2. However, the impact of ACE2 on SARS-CoV-2 susceptibility and the situation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Peng, Gong, Caifeng, Ma, Shaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712168/
https://www.ncbi.nlm.nih.gov/pubmed/33336018
http://dx.doi.org/10.1515/med-2020-0208
_version_ 1783618311976648704
author Ren, Peng
Gong, Caifeng
Ma, Shaohua
author_facet Ren, Peng
Gong, Caifeng
Ma, Shaohua
author_sort Ren, Peng
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is now a serious public health problem. Angiotensin-converting enzyme 2 (ACE2) recognized as the receptor of SARS-CoV is also necessary for SARS-CoV-2. However, the impact of ACE2 on SARS-CoV-2 susceptibility and the situation of malignant tumor patients in this outbreak are unclear. So, it is important to understand the expressions of ACE2 in different normal tissues and cancers. The results showed that the kidneys, duodenum, intestine, gallbladder and testis had the highest ACE2 expressions, followed by the colon, rectum and seminal vesicles. The lungs had a very low expression. ACE2 expressions were upregulated in renal cancer, gastrointestinal tumor and lung cancer. ACE2 expression levels may affect SARS-CoV-2 infection and severity. A total of 3,421 cases with COVID-19 have been collected. Among them, 43 cases (1.26%) had malignant tumor coexisting conditions. The rate of severe events for malignant tumor patients was 39.02% (16/41), while the rate of severe events for all patients was 10.79% (194/1,798). The clinical symptoms and signs were studied for the following three systems: respiratory (31–92%), digestive (10–13%) and urinary systems (3.38%). It seems that symptom severity is not related to protein expression levels. This might be the reason for SARS-CoV-2 showing higher regeneration index and susceptibility. More research is needed to explore the mechanisms and treatments.
format Online
Article
Text
id pubmed-7712168
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-77121682020-12-16 Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients Ren, Peng Gong, Caifeng Ma, Shaohua Open Med (Wars) Research Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is now a serious public health problem. Angiotensin-converting enzyme 2 (ACE2) recognized as the receptor of SARS-CoV is also necessary for SARS-CoV-2. However, the impact of ACE2 on SARS-CoV-2 susceptibility and the situation of malignant tumor patients in this outbreak are unclear. So, it is important to understand the expressions of ACE2 in different normal tissues and cancers. The results showed that the kidneys, duodenum, intestine, gallbladder and testis had the highest ACE2 expressions, followed by the colon, rectum and seminal vesicles. The lungs had a very low expression. ACE2 expressions were upregulated in renal cancer, gastrointestinal tumor and lung cancer. ACE2 expression levels may affect SARS-CoV-2 infection and severity. A total of 3,421 cases with COVID-19 have been collected. Among them, 43 cases (1.26%) had malignant tumor coexisting conditions. The rate of severe events for malignant tumor patients was 39.02% (16/41), while the rate of severe events for all patients was 10.79% (194/1,798). The clinical symptoms and signs were studied for the following three systems: respiratory (31–92%), digestive (10–13%) and urinary systems (3.38%). It seems that symptom severity is not related to protein expression levels. This might be the reason for SARS-CoV-2 showing higher regeneration index and susceptibility. More research is needed to explore the mechanisms and treatments. De Gruyter 2020-07-07 /pmc/articles/PMC7712168/ /pubmed/33336018 http://dx.doi.org/10.1515/med-2020-0208 Text en © 2020 Peng Ren et al., published by De Gruyter http://creativecommons.org/licenses/by/4.0 This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Research Article
Ren, Peng
Gong, Caifeng
Ma, Shaohua
Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients
title Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients
title_full Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients
title_fullStr Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients
title_full_unstemmed Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients
title_short Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients
title_sort evaluation of covid-19 based on ace2 expression in normal and cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712168/
https://www.ncbi.nlm.nih.gov/pubmed/33336018
http://dx.doi.org/10.1515/med-2020-0208
work_keys_str_mv AT renpeng evaluationofcovid19basedonace2expressioninnormalandcancerpatients
AT gongcaifeng evaluationofcovid19basedonace2expressioninnormalandcancerpatients
AT mashaohua evaluationofcovid19basedonace2expressioninnormalandcancerpatients